Johnson & Johnson $JNJ Stock Holdings Cut by Signal Advisors Wealth LLC

Key Points

• Signal Advisors Wealth LLC reduced its stake in Johnson & Johnson (NYSE:JNJ) by 25.2% in Q2, selling 2,153 shares, leaving its holding at 6,378 shares valued at approximately $974,000.
• Johnson & Johnson's stock is down 1.7% and has a market cap of $419.66 billion, with recent earnings reporting $2.77 EPS and quarterly revenue of $23.74 billion, exceeding expectations.
• The company recently declared a quarterly dividend of $1.30 per share, which equates to a 3.0% dividend yield and a payout ratio of 55.61%.

Signal Advisors Wealth LLC cut its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 25.2% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 6,378 shares of the company's stock after selling 2,153 shares during the period. Signal Advisors Wealth LLC's holdings in Johnson & Johnson were worth $974,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in JNJ. Highline Wealth Partners LLC lifted its holdings in shares of Johnson & Johnson by 51.8% in the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after buying an additional 86 shares during the period. Stone House Investment Management LLC purchased a new position in Johnson & Johnson in the 1st quarter valued at approximately $47,000. 1248 Management LLC purchased a new position in Johnson & Johnson in the 1st quarter valued at approximately $48,000. von Borstel & Associates Inc. purchased a new position in Johnson & Johnson during the first quarter worth $49,000. Finally, Capital A Wealth Management LLC purchased a new position in Johnson & Johnson during the fourth quarter worth $50,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president directly owned 178,013 shares of the company's stock, valued at $31,652,491.53. This represents a 24.08% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.16% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the company. Guggenheim restated a "neutral" rating and set a $167.00 price objective (up previously from $164.00) on shares of Johnson & Johnson in a report on Thursday, July 17th. Bank of America raised their price objective on Johnson & Johnson from $161.00 to $175.00 and gave the stock a "neutral" rating in a report on Thursday, July 17th. The Goldman Sachs Group lifted their target price on Johnson & Johnson from $185.00 to $186.00 and gave the company a "buy" rating in a report on Friday. JPMorgan Chase & Co. lifted their target price on Johnson & Johnson from $185.00 to $200.00 and gave the company a "neutral" rating in a report on Tuesday, September 16th. Finally, Erste Group Bank upgraded Johnson & Johnson from a "hold" rating to a "buy" rating in a report on Wednesday, July 23rd. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and ten have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $178.80.

Johnson & Johnson Stock Performance

Shares of NYSE:JNJ traded down $0.46 during trading on Monday, hitting $175.73. 1,576,983 shares of the company traded hands, compared to its average volume of 8,916,261. The stock has a market capitalization of $423.21 billion, a price-to-earnings ratio of 18.79, a PEG ratio of 2.24 and a beta of 0.40. The business's fifty day moving average is $172.80 and its 200-day moving average is $161.64. Johnson & Johnson has a one year low of $140.68 and a one year high of $181.16. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.68 by $0.09. The company had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The business's revenue was up 5.8% compared to the same quarter last year. During the same period in the prior year, the company earned $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, equities analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 3.0%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson's dividend payout ratio is 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.